A downtrend has been apparent in Third Harmonic Bio, Inc. (THRD) lately with too much selling pressure. The stock has declined 31.6% over the past four weeks. However, given the fact that it is ...

Third Harmonic Bio, Inc. (THRD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...

Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Third Harmonic Bio will halt non-THB335 research and cut 50% of its workforce while reviewing strategic options. Every week, our Whisper Index uncovers five overlooked stocks with big breakout ...

On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The company says the data ...

Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 433.54% ...